GlassScriptPhysician profile
Glenn Kellis Mcclaugherty
NPI 1619995669
$2,928.86
in general payments reported to CMS, 2019-2025
17 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $137 · 2021: $493 · 2022: $413 · 2023: $859 · 2024: $320 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,219 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.83 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $733.90 | 2019-2023 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $473.23 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $356.63 | 2019-2024 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $314.80 | 2019-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $281.40 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $220.96 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Novo Nordisk INC | $125.00 | 2019 | |
| Abbvie INC. | $97.75 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.55 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $45.85 | 2019-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $42.27 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $42.04 | 2019-2021 | |
| Indivior INC. | $41.20 | 2024 | Perseris |
| Allergan, INC. | $35.13 | 2019-2020 | |
| Lundbeck LLC | $30.50 | 2019-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.88 | 2019 | |
| Corium, LLC | $14.77 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Mcclaugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.